Eculizumab modifies outcomes in adults with atypical hemolytic uremic syndrome with acute kidney injury
M Cao, BN Leite, T Ferreiro, M Calvo… - American journal of …, 2018 - karger.com
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare disease associated with
congenital or acquired genetic abnormalities that result in uncontrolled complement …
congenital or acquired genetic abnormalities that result in uncontrolled complement …
[HTML][HTML] Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial
F Fakhouri, M Hourmant, JM Campistol… - American journal of …, 2016 - Elsevier
Background Atypical hemolytic uremic syndrome (aHUS) is a rare genetic life-threatening
disease of chronic uncontrolled complement activation leading to thrombotic …
disease of chronic uncontrolled complement activation leading to thrombotic …
Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic …
J Zuber, M Frimat, S Caillard, N Kamar… - Journal of the …, 2019 - journals.lww.com
Background Atypical hemolytic uremic syndrome (HUS) is associated with high recurrence
rates after kidney transplant, with devastating outcomes. In late 2011, experts in France …
rates after kidney transplant, with devastating outcomes. In late 2011, experts in France …
Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan
N Ito, H Hataya, K Saida, Y Amano, Y Hidaka… - Clinical and …, 2016 - Springer
Background Atypical hemolytic uremic syndrome (aHUS) is a severe life-threatening
disease with frequent progression to end-stage renal disease (ESRD). Eculizumab, a …
disease with frequent progression to end-stage renal disease (ESRD). Eculizumab, a …
Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B
RD Gilbert, DJ Fowler, E Angus, SA Hardy… - Pediatric …, 2013 - Springer
Background Atypical haemolytic uraemic syndrome (aHUS) is caused by dysregulated
complement activation. A humanised anti-C5 monoclonal antibody has recently become …
complement activation. A humanised anti-C5 monoclonal antibody has recently become …
Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab
B Puissant-Lubrano, S Puissochet, N Congy-Jolivet… - Clinical …, 2017 - Elsevier
Eculizumab is a monoclonal anti-C5 antibody used in the treatment of atypical hemolytic
uremic syndrome (aHUS). We monitored complement inhibition in 16 eculizumab-treated …
uremic syndrome (aHUS). We monitored complement inhibition in 16 eculizumab-treated …
[HTML][HTML] Eculizumab is an effective long-term treatment in patients with atypical hemolytic uremic syndrome (aHUS) previously receiving chronic plasma exchange …
C Licht, P Muus, C Legendre, KW Douglas… - Blood, 2011 - Elsevier
Abstract 3303 INTRODUCTION: Chronic uncontrolled complement activation drives
systemic thrombotic microangiopathy (TMA) and life-threatening complications in aHUS. In …
systemic thrombotic microangiopathy (TMA) and life-threatening complications in aHUS. In …
An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome
S Gastoldi, S Aiello, M Galbusera, M Breno… - Frontiers in …, 2023 - frontiersin.org
Introduction Comprehensive genetic analysis is essential to clinical care of patients with
atypical haemolytic uremic syndrome (aHUS) to reinforce diagnosis, and to guide treatment …
atypical haemolytic uremic syndrome (aHUS) to reinforce diagnosis, and to guide treatment …
Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings
S Tschumi, M Gugger, BS Bucher, M Riedl… - Pediatric …, 2011 - Springer
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy associated
with defective regulation of the alternative complement pathway. The prognosis for patients …
with defective regulation of the alternative complement pathway. The prognosis for patients …
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS
R Cofiell, A Kukreja, K Bedard, Y Yan… - Blood, The Journal …, 2015 - ashpublications.org
Atypical hemolytic uremic syndrome (aHUS) is a genetic, life-threatening disease
characterized by uncontrolled complement activation, systemic thrombotic microangiopathy …
characterized by uncontrolled complement activation, systemic thrombotic microangiopathy …